The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
Open accessAbstract
Parkinson's disease (PD) is a neurodegenerative disorder of uncertain pathogenesis characterized by the loss of the nigrostriatal dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Increased expression of cyclooxygenase type 2 (COX-2) and production of prostaglandin E 2 have been implicated in neurodegeneration in several pathological settings. Here we show that COX-2, the rate-limiting enzyme in prostaglandin E 2 synthesis, is up-regulated in brain dopaminergic neurons of both PD and MPTP mice. COX-2 induction occurs through a JNK/c-Jun-dependent mechanism after MPTP administration. We demonstrate that targeting COX-2 does not protect against MPTP-induced dopaminergic neurodegeneration by mitigating inflammation. Instead, we provide evidence that COX-2 inhibition prevents the formation of the oxidant species dopamine-quinone, which has been implicated in the pathogenesis of PD. This study supports a critical role for COX-2 in both the pathogenesis and selectivity of the PD neurodegenerative process. Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood–brain barrier, these drugs may be therapies for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette, J. C., Mahler, J. F., Kluckman, K. D., Ledford, A., Lee, C. A., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90125-6 · Cited by 1,082
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
Self-citationCyclo-Oxygenase-2 Gene Expression in Neurons Contributes to Ischemic Brain Damage
Nogawa, S., Zhang, F., Ross, M. E., & Iadecola, C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02746.1997 · Cited by 716
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Self-citationProstaglandin and thromboxane biosynthesis
Smith, W. L., Marnett, L. J., & DeWitt, D. L. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90054-p · Cited by 442
Cyclooxygenase-2: Molecular Biology, Pharmacology, and Neurobiology
O'Banion, M. K. (1999) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v13.i1.30 · Cited by 404
Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase
Hastings, T. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020919.x · Cited by 359
Cited by
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Self-citationTansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond
Ilieva, H., Polymenidou, M., & Cleveland, D. W. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908164 · Cited by 1,008
“Thus, in this chemically induced PD model, converging damage within astrocytes, microglia, and invading T cells, as well as the target neurons, creates an oxidative milieu detrimental to the neurons and which is probably further exacerbated by neuronally restricted oxidative pathways (Teismann et al., 2003; Hunot et a…”
Cyclooxygenase-2 (COX-2) in Inflammatory and Degenerative Brain Diseases
Minghetti, L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.9.901 · Cited by 779
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation
Nomura, D. K., Morrison, B. E., Blankman, J. L., Long, J. Z., Kinsey, S. G., Marcondes, M. C. G., Ward, A. M., Hahn, Y. K., Lichtman, A. H., Conti, B., et al. (2011) · Science · doi:10.1126/science.1209200 · Cited by 727
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Synopsis of arachidonic acid metabolism: A review
Hanna, V. S., & Hafez, E. A. A. (2018) · Journal of Advanced Research · doi:10.1016/j.jare.2018.03.005 · Cited by 596
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration
Musiek, E. S., Lim, M. M., Yang, G., Bauer, A. Q., Qi, L., Lee, Y., Roh, J. H., Ortiz-Gonzalez, X., Dearborn, J. T., Culver, J. P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70317 · Cited by 524
Targeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
Self-citationFormation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects
Bolton, J. L., & Dunlap, T. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00256 · Cited by 522
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 508
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 472
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
Molecular and cellular mechanisms of excitotoxic neuronal death
Wang, Y., & Qin, Z.-H. (2010) · Apoptosis · doi:10.1007/s10495-010-0481-0 · Cited by 445
Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases
Sonnweber, T., Pizzini, A., Nairz, M., Weiss, G., & Tancevski, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113285 · Cited by 440
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders
Reynolds, A., Laurie, C., Lee Mosley, R., & Gendelman, H. E. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)82016-2 · Cited by 432
Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, E. C., Przedborski, S., Rakic, P., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 426
Self-citationGlia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 424
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
Self-citationNeuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
Choi, S.-H., Aid, S., & Bosetti, F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.01.002 · Cited by 402
Martins, L. M., Morrison, A., Klupsch, K., Fedele, V., Moisoi, N., Teismann, P., Abuin, A., Grau, E., Geppert, M., Livi, G. P., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.22.9848-9862.2004 · Cited by 394
Self-citationNeuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Lee Mosley, R., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., Laurie, C., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 387
Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats
Jin, F., Wu, Q., Lu, Y.-F., Gong, Q.-H., & Shi, J.-S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.005 · Cited by 384
The MPTP model of Parkinson's disease
Smeyne, R. J., & Jackson-Lewis, V. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.017 · Cited by 377
Self-citationTheodore, S., Cao, S., McLean, P. J., & Standaert, D. G. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818e5e99 · Cited by 367
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363
Self-citationNeuroprotective Function of the PGE2EP2 Receptor in Cerebral Ischemia
McCullough, L., Wu, L., Haughey, N., Liang, X., Hand, T., Wang, Q., Breyer, R. M., & Andreasson, K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4485-03.2004 · Cited by 361
Pathogenesis of Parkinson's disease
Hirsch, E. C., Jenner, P., & Przedborski, S. (2013) · Movement Disorders · doi:10.1002/mds.25032 · Cited by 336
Self-citationRole of inflammation in neurodegenerative diseases
Minghetti, L. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000169752.54191.97 · Cited by 335
Niranjan, R. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8483-x · Cited by 327
Novel anti-inflammatory therapy for Parkinson's disease
Gao, H.-M., Liu, B., Zhang, W., & Hong, J.-S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00176-7 · Cited by 324
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322
Self-citationGarcía-Arencibia, M., González, S., de Lago, E., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2007) · Brain Research · doi:10.1016/j.brainres.2006.11.063 · Cited by 320
Drechsel, D. A., & Patel, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.008 · Cited by 314
Glutathione—a review on its role and significance in Parkinson's disease
Martin, H. L., & Teismann, P. (2009) · The FASEB Journal · doi:10.1096/fj.08-125443 · Cited by 314
Self-citationNeuroinflammatory processes in Parkinson's disease
Hirsch, E. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 296
Self-citationMancuso, C. (2007) · Frontiers in Bioscience · doi:10.2741/2130 · Cited by 294
Silva, R. M., Ries, V., Oo, T. F., Yarygina, O., Jackson‐Lewis, V., Ryu, E. J., Lu, P. D., Marciniak, S. M., Ron, D., Przedborski, S., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03428.x · Cited by 285
Self-citationKhan, M. M., Ahmad, A., Ishrat, T., Khan, M. B., Hoda, M. N., Khuwaja, G., Raza, S. S., Khan, A., Javed, H., Vaibhav, K., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.02.031 · Cited by 279
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
Self-citationCellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease
More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K. (2013) · Mediators of Inflammation · doi:10.1155/2013/952375 · Cited by 258
Self-citationNeurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Peng, B., Xiao, J., Wang, K., So, K.-F., Tipoe, G. L., & Lin, B. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5200-13.2014 · Cited by 255
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Sriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242
Candelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., & Fiebich, B. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-25 · Cited by 223
“Inhibition of COX-2 induction and/or activity has been proven to reduce brain injury after ischemia [46-50], excitotoxicity [47,51], and MPTPinduced neurodegeneration [52-54].”
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221
“Microglia may cause neuronal damage through the release of cytotoxic molecules, as supported by PD animal models [8].”
BackgroundSathe, K., Maetzler, W., Lang, J. D., Mounsey, R. B., Fleckenstein, C., Martin, H. L., Schulte, C., Mustafa, S., Synofzik, M., Vukovic, Z., et al. (2012) · Brain · doi:10.1093/brain/aws250 · Cited by 202
Self-citationAstrocyte–neuron interactions in neurological disorders
Ricci, G., Volpi, L., Pasquali, L., Petrozzi, L., & Siciliano, G. (2009) · Journal of Biological Physics · doi:10.1007/s10867-009-9157-9 · Cited by 155
Striatal Neuroinflammation Promotes Parkinsonism in Rats
Choi, D.-Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., Shin, E.-J., Kim, H.-C., Gash, D. M., & Bing, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005482 · Cited by 141
Self-citationCould a loss of α‐synuclein function put dopaminergic neurons at risk?
Perez, R. G., & Hastings, T. G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02423.x · Cited by 133
Fluoxetine protects neurons against microglial activation-mediated neurotoxicity
Zhang, F., Zhou, H., Wilson, B. C., Shi, J.-S., Hong, J.-S., & Gao, H.-M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70066-9 · Cited by 123
“Reduction in these inflammatory factors by pharmacological inhibition or genetic deletion provides neuroprotective effects in various experimental settings [2,15,16].”
BackgroundWard, N. L., & Lamanna, J. C. (2004) · Neurological Research · doi:10.1179/016164104x3798 · Cited by 122
Yang, Y.-L., Cheng, X., Li, W.-H., Liu, M., Wang, Y.-H., & Du, G.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030491 · Cited by 116
Expression of mutant alpha-synuclein modulates microglial phenotype in vitro
Rojanathammanee, L., Murphy, E. J., & Combs, C. K. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-44 · Cited by 106
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
Johansson, J. U., Pradhan, S., Lokteva, L. A., Woodling, N. S., Ko, N., Brown, H. D., Wang, Q., Loh, C., Cekanaviciute, E., Buckwalter, M., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2203-13.2013 · Cited by 96
“, 2002) or nonsteroidal anti-inflammatory drugs (Teismann and Ferger, 2001; Teismann et al., 2003) prevent DA neuron loss in the MPTP model.”
BackgroundMolecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity
Teismann, P., Sathe, K., Bierhaus, A., Leng, L., Martin, H. L., Bucala, R., Weigle, B., Nawroth, P. P., & Schulz, J. B. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.006 · Cited by 75
Self-citationBlais, V., Turrin, N. P., & Rivest, S. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03480.x · Cited by 72
Garcia, P., Jürgens‐Wemheuer, W., Uriarte Huarte, O., Michelucci, A., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2022) · Glia · doi:10.1002/glia.24149 · Cited by 65
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E.-S. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01192-2 · Cited by 47
Kim, S. R., Chung, E. S., Bok, E., Baik, H. H., Chung, Y. C., Won, S. Y., Joe, E., Kim, T. H., Kim, S. S., Jin, M. Y., et al. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22318 · Cited by 43
“, 2008) These results suggest that microglia represent an important source of COX-2 and prostanoids in the brain, although COX-2 expression is also localized to neurons (Teismann et al., 2003).”
BackgroundLopez de Maturana, R., Aguila, J. C., Sousa, A., Vazquez, N., del Rio, P., Aiastui, A., Gorostidi, A., Lopez de Munain, A., & Sanchez-Pernaute, R. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.018 · Cited by 38
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33
Dhiman, S., Mannan, A., Taneja, A., Mohan, M., & Singh, T. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122537 · Cited by 25
Ayoub, S. S., Wood, E. G., Hassan, S.-U., & Bolton, C. (2011) · Inflammation Research · doi:10.1007/s00011-011-0352-3 · Cited by 19
Metadata
- Authors
- Teismann, P., Tieu, K., Choi, D.-K., Wu, D.-C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V., & Przedborski, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-04-17
- Volume
- 100
- Issue
- 9
- Pages
- 5473-5478
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2056546282
- Cited by
- 660
- References
- 27
- FWCI
- 26.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.